Tommasi Chiara, Ceccherini-Silberstein Francesca, D'Arrigo Roberta, Bellagamba Rita, Tempestilli Massimo, Dessì Carlo, Santoro Maria M, Forbici Federica, Nicastri Emanuele, Pucillo Leopoldo P, Perno Carlo F, Narciso Pasquale
National Institute for Infectious Diseases, INMI, L Spallanzani, Rome, Italy.
Scand J Infect Dis. 2010 Mar;42(3):237-9. doi: 10.3109/00365540903447018.
In patients with virological failure during highly active antiretroviral therapy (HAART) and drug resistance, guidelines recommend the achievement of maximal virological suppression by the use of a new regimen with at least 2 active drugs. We describe the clinical outcome of a heavily antiretroviral-experienced patient who experienced early failure to raltegravir.
在接受高效抗逆转录病毒治疗（HAART）期间出现病毒学失败且有耐药性的患者中，指南建议使用至少包含2种活性药物的新方案来实现最大程度的病毒学抑制。我们描述了一名有大量抗逆转录病毒治疗经历的患者的临床结局，该患者对raltegravir早期治疗失败。
